Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening

被引:11
|
作者
Zhou, Yeheng [1 ,2 ]
Peng, Jiale [1 ]
Li, Penghua [1 ]
Du, Haibo [1 ]
Li, Yaping [1 ]
Li, Yingying [1 ]
Zhang, Li [1 ]
Sun, Wei [2 ]
Liu, Xingyong [1 ]
Zuo, Zhili [1 ,2 ]
机构
[1] Sichuan Univ Sci & Engn, Sch Chem Engn, Zigong, Peoples R China
[2] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China
关键词
IDO1; Molecular docking; HipHop pharmacophore; 3D-QSAR; PAINS; PHENYL BENZENESULFONYLHYDRAZIDES; THERAPEUTIC TARGET; CRYSTAL-STRUCTURES; DERIVATIVES; DOCKING; MECHANISM;
D O I
10.1016/j.compbiolchem.2018.11.024
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this study, a combination of virtual screening methods were utilized to identify novel potential indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. A series of IDOL potential inhibitors were identified by a combination of following steps: Lipinski's Rule of Five, Veber rules filter, molecular docking, HipHop pharmacophores, 3D-Quantitative structure activity relationship (3D-QSAR) studies and Pan-assay Interference Compounds (PAINS) filter. Three known categories of IDO1 inhibitors were used to constructed pharmacophores and 3D-QSAR models. Four point pharmacophores (RI-IDA) of IDOL inhibitors were generated from the training set. The 3D-QSAR models were obtained using partial least squares (PLS) analyze based on the docking conformation alignment from the training set. The leave-one-out correlation (q(2)) and non-cross-validated correlation coefficient (r(pred)(2)) of the best CoMFA model were 0.601 and 0.546, and the ones from the best CoMSIA model were 0.506 and 0.541, respectively. Six hits from Specs database were identified and analyzed to confirm their binding modes and key interactions to the amino acid residues in the protein. This work may provide novel backbones for new generation of inhibitors of IDOL.
引用
收藏
页码:306 / 316
页数:11
相关论文
共 50 条
  • [1] Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Wang, Xiu-Xiu
    Sun, Si-Yu
    Dong, Qing-Qing
    Wu, Xiao-Xiang
    Tang, Wei
    Xing, Ya-Qun
    MEDCHEMCOMM, 2019, 10 (10) : 1740 - 1754
  • [2] Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
    Xu, Xi
    Ren, Jie
    Ma, Yinghe
    Liu, Hongting
    Rong, Quanjin
    Feng, Yifan
    Wang, Yameng
    Cheng, Yu
    Ge, Ruijia
    Li, Zhiyu
    Bian, Jinlei
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 250 - 263
  • [3] A Novel High Throughput Virtual Screening Protocol to Discover New Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Xu, Haojie
    Song, Yunlong
    Yang, Qing
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2017, 65 (08) : 714 - 717
  • [4] Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1)
    Roehrig, Ute F.
    Michielin, Olivier
    Zoete, Vincent
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (24) : 17690 - 17705
  • [5] Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors
    Singh, Rahul
    Salunke, Deepak B.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [6] Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold
    Brant, Michael G.
    Goodwin-Tindall, Jake
    Stover, Kurt R.
    Stafford, Paul M.
    Wu, Fan
    Meek, Autumn R.
    Schiavini, Paolo
    Wohnig, Stephanie
    Weaver, Donald F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (02): : 131 - 136
  • [7] Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Rohrig, Ute F.
    Majjigapu, Somi Reddy
    Reynaud, Aline
    Pojer, Florence
    Dilek, Nahzli
    Reichenbach, Patrick
    Ascencao, Kelly
    Irving, Melita
    Coukos, George
    Vogel, Pierre
    Michielin, Olivier
    Zoete, Vincent
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (04) : 2205 - 2227
  • [8] Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1)
    Fung, Sai-Parng S.
    Wang, Haiyan
    Tomek, Petr
    Squire, Christopher J.
    Flanagan, Jack U.
    Palmer, Brian D.
    Bridewell, David J. A.
    Tijono, Sofian M.
    Jamie, Joanne F.
    Ching, Lai-Ming
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (24) : 7595 - 7603
  • [9] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
    Moyer, Benjamin J.
    Rojas, Itzel Y.
    Murray, Iain A.
    Lee, Seokwon
    Hazlett, Haley F.
    Perdew, Gary H.
    Tomlinson, Craig R.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 323 : 74 - 80
  • [10] Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening
    Zhang, Guoqing
    Xing, Jing
    Wang, Yulan
    Wang, Lihao
    Ye, Yan
    Lu, Dong
    Zhao, Jihui
    Luo, Xiaomin
    Zheng, Mingyue
    Yan, Shiying
    FRONTIERS IN PHARMACOLOGY, 2018, 9